Document Type
Article
Publication Date
3-27-2020
Identifier/URL
71166644 (Orcid)
Abstract
Objective: To evaluate the association of cord blood magnesium concentrations at the time of birth with cerebral palsy (CP) and neonatal death. Study Design: A secondary analysis of a randomized controlled trial that randomized women at imminent risk of delivery between 24 and 31 weeks of gestation to receive magnesium sulfate or placebo. This ‘study’s primary outcome was a composite of either moderate to severe CP or death. Secondary outcomes included CP, moderate to severe CP, neonatal death, and neonatal head ultrasound findings. We used a logistic regression model to evaluate the relationship between the concentration of magnesium in cord blood and study outcomes. Results: A total of 668 women were included in this analysis and were randomized to magnesium sulfate at 28 ± 2.5 ‘weeks’ gestation. Cord blood magnesium concentrations were not associated with the primary outcome of infant death by 1 year of age or moderate or severe cerebral palsy, as assessed at or beyond 2 years of age (aOR 0.95 (0.67, 1.36), p = 0.79). Cord blood magnesium concentrations were not associated with any of the secondary outcome measurements. Conclusion: Cord blood magnesium concentrations were not associated with moderate to severe cerebral palsy or death, or other neurodevelopmental or sonographic outcomes.
Repository Citation
Dixon, C. L.,
Liu, X.,
Balch, A.,
Costantine, M.,
& Sherwin, C. M.
(2020). Investigation Into the Reproducibility of the Association of Cord Blood Magnesium Concentration and Cerebral Palsy or Death in Children. Research Square.
https://corescholar.libraries.wright.edu/pediatrics/671
DOI
10.21203/rs.3.rs-19283/v1
Comments
This work is licensed under a Creative Commons Attribution 4.0 International License.